They may suggest: Lowering the dose or slowing the dosing schedule Avoiding foods that may trigger side effects (e.g., fatty foods triggering nausea) Managing symptoms through hydration, dietary changes, or injection timing Who shouldnt take retatrutide
Ludwig, M
It includes multiple trials studying retatrutide in different populations: TRIUMPH-1 (obesity/overweight without type 2 diabetes, NCT05929066), TRIUMPH-3 (severe obesity + cardiovascular disease, NCT05882045), TRIUMPH-9 (dose-escalation in obesity, NCT07357415), and TRIUMPH-Outcomes (cardiovascular and kidney outcomes in adults with obesity, NCT06383390)
Kirichenko TV, Markina YV, Bogatyreva AI, Tolstik TV, Varaeva YR, Starodubova AV
Adv Drug Delivery Rev
Reasons for discontinuation of GLP1 receptor agonists: Data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes